<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5056">
  <stage>Registered</stage>
  <submitdate>19/06/2015</submitdate>
  <approvaldate>19/06/2015</approvaldate>
  <nctid>NCT02480348</nctid>
  <trial_identification>
    <studytitle>Medtronic RevElution Trial</studytitle>
    <scientifictitle>Medtronic Polymer-Free Drug-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions</scientifictitle>
    <utrn />
    <trialacronym>RevElution</trialacronym>
    <secondaryid>Version 4.0, 04 AUG 2017</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Coronary Artery Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Polymer-free DES (Drug Eluting Stent)

Experimental: Polymer-free DES (Drug Eluting Stent) - 


Treatment: devices: Polymer-free DES (Drug Eluting Stent)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Late lumen loss (LLL, in-stent) at 9 months post-procedure as measured by quantitative coronary angiography.</outcome>
      <timepoint>9 months</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must be an acceptable candidate for percutaneous coronary intervention, stenting, &amp;
             emergent coronary artery bypass graft (CABG) surgery

          -  Must have evidence of ischemic heart disease

          -  Must require treatment of either a) a single target lesion amenable to treatment with
             a 2.25 mm - 3.50 mm stent OR b) two target lesions located in separate target vessels,
             with at least one of the target lesions amenable to treatment with a 2.25 mm - 3.50 mm
             mm study stent

          -  Target lesion(s) must be de novo lesion(s) in native coronary artery(ies)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin,
             thienopyridines, cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer
             coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be adequately
             pre-medicated

          -  History of an allergic reaction or significant sensitivity to drugs such as
             zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative

          -  History of a stroke or transient ischemic attack (TIA) within the prior 6 months

          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months

          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions

          -  Concurrent medical condition with a life expectancy of less than 5 years

          -  Currently participating in an investigational drug or another device trial that has
             not completed the primary endpoint

          -  Documented left ventricular ejection fraction (LVEF) &lt; 30% at the most recent
             evaluation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/02/2021</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,QLD,SA</recruitmentstate>
    <hospital>Eastern Heart Clinic - Prince of Wales Hospital - Sydney</hospital>
    <hospital>The Prince Charles Hospital - Chermside</hospital>
    <hospital>St. Andrew's Hospital - Adelaide</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Wesley Hospital / HeartCare Partners - Auchenflower</hospital>
    <hospital>Flinders Medical Center - Bedford Park</hospital>
    <hospital>St. Vincent's Hospital - Darlinghurst</hospital>
    <hospital>Royal Brisbane &amp; Women's Hospital - Herston</hospital>
    <hospital>Monash Medical Center - Melbourne</hospital>
    <hospital>Northern Hospital - Melbourne</hospital>
    <hospital>Fiona Stanley Hospital - Murdoch</hospital>
    <hospital>John Hunter Hospital - New Lambton</hospital>
    <hospital>Royal North Shore Hospital - St Leonards</hospital>
    <postcode>2031 - Sydney</postcode>
    <postcode>4032 - Chermside</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode> - Auchenflower</postcode>
    <postcode>5042 - Bedford Park</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>4029 - Herston</postcode>
    <postcode>3168 - Melbourne</postcode>
    <postcode> - Melbourne</postcode>
    <postcode> - Murdoch</postcode>
    <postcode> - New Lambton</postcode>
    <postcode>2065 - St Leonards</postcode>
    <countryoutsideaustralia>
      <country>Brazil</country>
      <state>SÃ£o Paulo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Medtronic Vascular</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to evaluate the clinical safety and efficacy of the Polymer-Free
      Drug-Eluting coronary stent system for the treatment of de novo lesions in native coronary
      arteries with a reference vessel diameter (RVD) that allows use of stents between 2.25 and
      3.50 mm in diameter.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02480348</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>